Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.34M | 3.06M | 1.24M | 2.20M | 881.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.94M | 8.87M | 4.35M | 10.80M | 5.68M |
| Operating Income | -5.94M | -8.87M | -4.35M | -10.80M | -5.68M |
| Income Before Tax | -5.53M | 4.17M | -9.58M | -12.71M | -5.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.53M | 4.17M | -9.58M | -12.71M | -5.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.53M | 4.17M | -9.58M | -12.71M | -5.51M |
| EBIT | -5.94M | -8.87M | -4.35M | -10.80M | -5.68M |
| EBITDA | -5.91M | -8.85M | -4.33M | -10.78M | -5.65M |
| EPS Basic | -0.59 | 0.51 | -1.50 | -1.99 | -2.14 |
| Normalized Basic EPS | -0.37 | 0.32 | -0.94 | -1.24 | -1.34 |
| EPS Diluted | -0.59 | -1.00 | -1.50 | -1.99 | -2.14 |
| Normalized Diluted EPS | -0.37 | 0.31 | -0.94 | -1.24 | -1.34 |
| Average Basic Shares Outstanding | 9.38M | 8.25M | 6.40M | 6.40M | 2.57M |
| Average Diluted Shares Outstanding | 9.38M | 8.46M | 6.40M | 6.40M | 2.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |